Simone Ragaini
YOU?
Author Swipe
View article: Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL)
Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL) Open
Background: Mantle Cell Lymphoma (MCL) is an aggressive malignancy with variable clinical behavior, largely reflecting the underlying molecular heterogeneity. The genomic landscape of MCL encompasses gene mutations with strong prognostic i…
View article: Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project
Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project Open
Introduction The TRIANGLE trial (Dreyling et al, Lancet 2024) compared three treatment arms in untreated, younger patients with mantle cell lymphoma (MCL): arm I (IR-CHOP/R-DHAP + ibrutinib maintenance [Im]), arm A+I (IR-CHOP/R-DHAP + ASCT…
View article: Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target Open
Mantle cell lymphoma (MCL) is a B‐cell malignancy characterized by t(11;14)(q13;q32) translocation and heterogeneous clinical behavior. Advances in risk stratification enabled the distinction of conventional MCL (cMCL) from non‐nodal MCL (…
View article: Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial Open
Although recent evidence suggests that myeloid clonal hematopoiesis (M-CH) may influence lymphoma clinical outcome, its impact in mantle cell lymphoma (MCL) remains unclear. Here, we report a comprehensive next-generation sequencing–based …
View article: Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The <scp>STRIDER</scp> study
Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The <span>STRIDER</span> study Open
Background Relapse and refractory (R/R) rates after first‐line R‐CHOP in diffuse large B cell lymphomas (DLBCL) are ~40% and ~15% respectively. Aims We conducted a retrospective real‐world analysis aimed at evaluating clinical outcomes of …
View article: MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial
MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial Open
Background. Despite durable clinical responses achieved by chemo-immunotherapy in follicular lymphoma (FL) patients, most of them eventually relapse. Actually, minimal residual disease (MRD) analysis based on the detection of BCL2::IGH rea…
View article: Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study
Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study Open
Introduction: Patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) have poor outcome. Time to first relapse or progression (POD) has been consistently shown to be an independent predictor of survival, with patients experie…
View article: Efficacy of rituximab in anti‐myelin‐associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow‐up
Efficacy of rituximab in anti‐myelin‐associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow‐up Open
Background and purpose We evaluated the clinical and neurophysiological efficacy of rituximab (RTX) in a neurophysiologically homogeneous group of patients with monoclonal gammopathy and immunoglobulin M (IgM) anti‐myelin‐associated glycop…
View article: P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL.
P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL. Open
Background: Mantle cell lymphoma (MCL) is characterized by a highly restricted immunoglobulin heavy chain (IGH) gene repertoire with stereotyped IGHV CDR3s, strongly implying a role for antigen-driven selection. Nonetheless, differently fr…
View article: P1256: A NOVEL DROP-OFF DIGITAL PCR ASSAY FOR CXCR4 MUTATION SCREENING IN IGM GAMMOPATHIES: FIRST DATA FROM THE FONDAZIONE ITALIANA LINFOMI BIO-WM STUDY
P1256: A NOVEL DROP-OFF DIGITAL PCR ASSAY FOR CXCR4 MUTATION SCREENING IN IGM GAMMOPATHIES: FIRST DATA FROM THE FONDAZIONE ITALIANA LINFOMI BIO-WM STUDY Open
Background: In IgM gammopathies: Waldenström’s Macroglobulinemia (WM) and IgM gammopathy of uncertain significance (IgM-MGUS), MYD88L265P and CXCR4S338X are the most frequent mutations, and both have clinical implications in WM. Recent stu…
View article: Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry
Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry Open
Data on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease …
View article: HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience
HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience Open
Hepatitis B virus reactivation (HBVr) can develop in HBV surface antigen (HBsAg) positive or HBsAg-negative and anti-hepatitis B core antigen antibodies (anti-HBc) positive (past HBV infection) patients receiving immuno-chemotherapy for he…
View article: An <i>IDO1</i>-related immune gene signature predicts overall survival in acute myeloid leukemia
An <i>IDO1</i>-related immune gene signature predicts overall survival in acute myeloid leukemia Open
The contribution of the bone marrow (BM) immune microenvironment to acute myeloid leukemia (AML) development is well-known, but its prognostic significance is still elusive. Indoleamine 2,3-dioxygenase 1 (IDO1), which is negatively regulat…
View article: COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment
COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment Open
As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to spread with more than 131 million cases confirmed worldwide (as of April 6, 2021), patients treated for hematological disorders with concurrent SARS-…
View article: Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia
Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia Open
Background. Bendamustine is a cytotoxic alkylating drug with a broad range of indications as a single agent or in combination therapy in lymphoid neoplasia patients. However, its tolerability in elderly patients is still debated. Methods: …
View article: Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma Open
Minimal residual disease (MRD) monitoring by PCR methods is a strong and standardized predictor of clinical outcome in mantle cell lymphoma (MCL) and follicular lymphoma (FL). However, about 20% of MCL and 40% of FL patients lack a reliabl…
View article: MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia Open
Introduction Clinical response and chemosensitivity of relapse or refractory AML patients were evaluated after rescue and bridge‐to‐transplant MEC (mitoxantrone, etoposide, and cytarabine) regimen. Methods and Patients Fifty‐five consecuti…
View article: PB2324 LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE
PB2324 LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE Open
Background: The role of autologous stem cell transplantation (ASCT) as consolidation therapy in acute myeloid leukemia (AML) remains unclear although most studies comparing ASCT with repeated cycles of intensive chemotherapy demonstrated a…
View article: PB1726 DOUBLE FLUDARABINE‐BASED INDUCTION AND INFECTIVE RISK: THE BOLOGNA EXPERIENCE.
PB1726 DOUBLE FLUDARABINE‐BASED INDUCTION AND INFECTIVE RISK: THE BOLOGNA EXPERIENCE. Open
Background: “3+7” represents the current standard of care for acute myeloid leukemia (AML). Fludarabine‐based regimens have limited application due to the absence of survival benefit and prolonged hematological toxicity after 2 nd cycle. I…